MIGA2

Across TCGA pan-cancer cohorts, MIGA2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MIGA2 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MIGA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIGA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, THYM, and LUAD are the cancer types where MIGA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.118	0.768	<.001	48	view →
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUAD	DFS	Median	IV	0.045	0.717	<.001	27	view →
UCEC	OS	Median	All	1.000	0.657	.015	16	view →
COAD	OS	Median	III,IV	0.089	0.781	<.001	15	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MIGA2–HNSC (OS)

Open the HNSC breakdown →